Wegovy is FDA-approved for long-term use with no set stopping point. The label specifically says it is indicated to “reduce excess body weight and maintain weight reduction long term,” which means the medication is designed to be taken indefinitely as long as it continues to work and you tolerate it well. Most people reach the full maintenance dose by week 17 and stay on it from there.
Why Wegovy Is Meant to Be Ongoing
Unlike short-term weight loss interventions, Wegovy treats obesity as a chronic condition, similar to how blood pressure medication manages hypertension over a lifetime. The FDA approved it for ongoing use in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related health condition. It also carries an approval for reducing the risk of heart attack, stroke, and cardiovascular death in adults who already have heart disease along with obesity or overweight.
There is no built-in timeline where your doctor is expected to take you off the medication. Clinical trials studied participants for up to two years or more, and the label’s maintenance phase begins at week 17 with no endpoint specified.
The Dose Escalation Timeline
You don’t start at the full dose. Wegovy uses a gradual ramp-up over about four months to reduce nausea and other gut-related side effects:
- Weeks 1 through 4: 0.25 mg once weekly
- Weeks 5 through 8: 0.5 mg once weekly
- Weeks 9 through 12: 1 mg once weekly
- Weeks 13 through 16: 1.7 mg once weekly
- Week 17 onward: 2.4 mg once weekly (maintenance)
If side effects are too intense at any step, the escalation can be paused for an extra four weeks before moving up. Some people stay at 1.7 mg as their maintenance dose if they can’t tolerate 2.4 mg. Both are considered acceptable long-term doses.
What Happens When You Stop
This is the main reason Wegovy is prescribed without a defined end date. The medication works by mimicking a gut hormone that signals fullness to your brain. When you stop taking it, that signal disappears. Researchers at the University of Cambridge describe it plainly: stopping the drug is like taking your foot off the brake, and weight regain tends to be rapid.
Studies show that people who discontinue do regain a significant portion of their lost weight, though on average they still keep off about a quarter of what they lost. The drug may also create longer-lasting changes in hormone levels and appetite regulation that persist for some time after stopping, but these effects aren’t strong enough to prevent most of the weight from returning. This biological reality is the core reason doctors generally recommend staying on the medication if it’s working for you.
Long-Term Safety Considerations
Because Wegovy is meant to be taken for years, the safety profile over extended use matters. Most side effects are gastrointestinal, especially nausea and diarrhea, and these tend to be worst during the dose escalation period and improve over time.
A few rarer risks are worth knowing about for long-term use. Pancreatitis occurs in fewer than 1% of patients and requires stopping the medication permanently if it develops. Gallstones affect fewer than 2% of patients, a risk that increases with rapid weight loss in general. The FDA label also carries a boxed warning about thyroid tumors found in rodent studies, though it remains unknown whether this applies to humans. People with a personal or family history of medullary thyroid carcinoma should not take the drug.
The SELECT trial, which followed over 17,000 participants with heart disease, found that semaglutide at the 2.4 mg dose reduced major cardiovascular events by 20% compared to placebo. For people with heart failure specifically, the benefit was even more pronounced, with a 28% reduction in events. Discontinuation rates due to side effects were similar across risk groups, suggesting the drug is generally well tolerated even in sicker populations over extended periods.
Insurance May Limit Your Coverage Timeline
Even though the FDA places no limit on how long you can take Wegovy, your insurance plan might. Many insurers require prior authorization and approve the medication in blocks. Maryland Medicaid, for example, initially authorizes only four months, then extends coverage for six more months if the original criteria are still met. Private insurers vary widely, but reauthorization reviews every 6 to 12 months are common.
These reviews typically check that you still meet the BMI or weight-related criteria and that the medication is producing results. If your insurer denies continued coverage, your prescriber can often file an appeal, especially if you have documented weight loss or cardiovascular risk reduction. Out-of-pocket costs without insurance can be substantial, which makes understanding your plan’s reauthorization process important early on.
Practical Factors That Affect Duration
Beyond the medical picture, a few real-world issues shape how long people actually stay on Wegovy. Supply shortages have periodically interrupted access, forcing some patients to pause treatment or switch to alternative medications. If you’re off the drug for an extended period, your doctor may restart you at a lower dose and escalate again rather than jumping back to the maintenance level.
Some people also reach a point where they’ve lost a significant amount of weight and want to try maintaining it through diet and exercise alone. This is a personal decision, but the data strongly suggests that the biological drivers of weight regain don’t go away just because you’ve kept weight off for a year or two on medication. If you’re considering stopping, having a clear plan with your provider and realistic expectations about potential regain makes a meaningful difference in how the transition goes.